Hologic, Inc. revised earnings guidance for the Fiscal year 2024. For the year, the Company expects revenues of $4,000 million to $4,050 million compared to previous guidance of $3,990 million to $4,065 million and GAAP EPS of $3.45 to $3.55 compared to previous guidance of $3.52 to $3.67.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
75.02 USD | +0.09% | -0.16% | +5.00% |
May. 09 | Argus Adjusts Price Target on Hologic to $95 From $89 | MT |
May. 06 | Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.00% | 17.51B | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 64.15B | |
+16.92% | 53.72B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024